Cargando…

Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors

Polytrauma is one of the disorders with the greatest economic impact on healthcare in society and one predictor for poor outcome is cardiac damage. Interleukin 33 receptors (IL-33R) and galectin-3 are two new potential cardiac trauma biomarkers that are the subjects of this investigation. Additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Birte, Voth, Maika, Rottluff, Katrin, Marzi, Ingo, Henrich, Dirk, Leppik, Liudmila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659247/
https://www.ncbi.nlm.nih.gov/pubmed/36362577
http://dx.doi.org/10.3390/jcm11216350
_version_ 1784830154325884928
author Weber, Birte
Voth, Maika
Rottluff, Katrin
Marzi, Ingo
Henrich, Dirk
Leppik, Liudmila
author_facet Weber, Birte
Voth, Maika
Rottluff, Katrin
Marzi, Ingo
Henrich, Dirk
Leppik, Liudmila
author_sort Weber, Birte
collection PubMed
description Polytrauma is one of the disorders with the greatest economic impact on healthcare in society and one predictor for poor outcome is cardiac damage. Interleukin 33 receptors (IL-33R) and galectin-3 are two new potential cardiac trauma biomarkers that are the subjects of this investigation. Additionally, this study assesses pre-existing cardiac damage or risk factors as predictors of cardiac damage after polytrauma. This retrospective study includes 107 polytraumatized patients with an ISS ≥16 admitted in a Level 1 Trauma Centre. Plasma samples were taken at admission. IL-33R and galectin-3 concentrations were detected in plasma samples by ELISA. Both did not correlate with the cardiac damage measured by troponin. Next to troponin, IL-33R was increased in patients with pre-existing cardiac comorbidities. In the subgroup of patients with cardiac comorbidities, the BMI and the initial blood sugar level were significantly increased compared to patients without cardiac comorbidities. Galectin-3 and IL-33R were shown to not correlate with cardiac damage. However, our data suggests that IL-33R protein should be revised in future studies as a marker of cardiac comorbidities. Further, our data indicate that patients with cardiac comorbidities represent a separate group of polytrauma patients characterized by higher concentrations of troponin, IL-33R, BMI and initial sugar level.
format Online
Article
Text
id pubmed-9659247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96592472022-11-15 Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors Weber, Birte Voth, Maika Rottluff, Katrin Marzi, Ingo Henrich, Dirk Leppik, Liudmila J Clin Med Article Polytrauma is one of the disorders with the greatest economic impact on healthcare in society and one predictor for poor outcome is cardiac damage. Interleukin 33 receptors (IL-33R) and galectin-3 are two new potential cardiac trauma biomarkers that are the subjects of this investigation. Additionally, this study assesses pre-existing cardiac damage or risk factors as predictors of cardiac damage after polytrauma. This retrospective study includes 107 polytraumatized patients with an ISS ≥16 admitted in a Level 1 Trauma Centre. Plasma samples were taken at admission. IL-33R and galectin-3 concentrations were detected in plasma samples by ELISA. Both did not correlate with the cardiac damage measured by troponin. Next to troponin, IL-33R was increased in patients with pre-existing cardiac comorbidities. In the subgroup of patients with cardiac comorbidities, the BMI and the initial blood sugar level were significantly increased compared to patients without cardiac comorbidities. Galectin-3 and IL-33R were shown to not correlate with cardiac damage. However, our data suggests that IL-33R protein should be revised in future studies as a marker of cardiac comorbidities. Further, our data indicate that patients with cardiac comorbidities represent a separate group of polytrauma patients characterized by higher concentrations of troponin, IL-33R, BMI and initial sugar level. MDPI 2022-10-27 /pmc/articles/PMC9659247/ /pubmed/36362577 http://dx.doi.org/10.3390/jcm11216350 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Weber, Birte
Voth, Maika
Rottluff, Katrin
Marzi, Ingo
Henrich, Dirk
Leppik, Liudmila
Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors
title Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors
title_full Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors
title_fullStr Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors
title_full_unstemmed Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors
title_short Evaluation of IL-33R and Galectin-3 as New Biomarkers of Cardiac Damage after Polytrauma—Association with Cardiac Comorbidities and Risk Factors
title_sort evaluation of il-33r and galectin-3 as new biomarkers of cardiac damage after polytrauma—association with cardiac comorbidities and risk factors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659247/
https://www.ncbi.nlm.nih.gov/pubmed/36362577
http://dx.doi.org/10.3390/jcm11216350
work_keys_str_mv AT weberbirte evaluationofil33randgalectin3asnewbiomarkersofcardiacdamageafterpolytraumaassociationwithcardiaccomorbiditiesandriskfactors
AT vothmaika evaluationofil33randgalectin3asnewbiomarkersofcardiacdamageafterpolytraumaassociationwithcardiaccomorbiditiesandriskfactors
AT rottluffkatrin evaluationofil33randgalectin3asnewbiomarkersofcardiacdamageafterpolytraumaassociationwithcardiaccomorbiditiesandriskfactors
AT marziingo evaluationofil33randgalectin3asnewbiomarkersofcardiacdamageafterpolytraumaassociationwithcardiaccomorbiditiesandriskfactors
AT henrichdirk evaluationofil33randgalectin3asnewbiomarkersofcardiacdamageafterpolytraumaassociationwithcardiaccomorbiditiesandriskfactors
AT leppikliudmila evaluationofil33randgalectin3asnewbiomarkersofcardiacdamageafterpolytraumaassociationwithcardiaccomorbiditiesandriskfactors